Evidence map›Paper›PMID 35664590›Full record

ArticleACS omega2022

Discovery of Anilino-1,4-naphthoquinones as Potent EGFR Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Comprehensive Molecular Modeling.

Panupong Mahalapbutr, Ronnakorn Leechaisit, Anusit Thongnum, Duangjai Todsaporn, Veda Prachayasittikul, Thanyada Rungrotmongkol, Supaluk Prachayasittikul, Somsak Ruchirawat, Virapong Prachayasittikul, Ratchanok Pingaew

Abstract read
In one paragraph

Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Discovery ofJournal of enzyme inhibition and medicinal chemistry · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Anilino-1,4-naphthoquinones as potent mushroom tyrosinase inhibitors:Journal of enzyme inhibition and medicinal chemistry · 2024
    Article
  14. Article
  15. Article
  16. Sulfonylated Indeno[1,2-ACS omega · 2023
    Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Panupong MahalapbutrDepartment of Biochemistry, and Center for Translational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.ORCID https://orcid.org/0000-0003-4389-334X
Ronnakorn LeechaisitDepartment of Chemistry, Faculty of Science, Srinakharinwirot University, Bangkok 10110, Thailand.
Anusit ThongnumDepartment of Physics, Faculty of Science, Srinakharinwirot University, Bangkok 10110, Thailand.ORCID https://orcid.org/0000-0003-3272-5797
Duangjai TodsapornStructural and Computational Biology Research Unit, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.
Veda PrachayasittikulCenter of Data Mining and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Bangkok 10700, Thailand.ORCID https://orcid.org/0000-0001-6338-3721
Thanyada RungrotmongkolStructural and Computational Biology Research Unit, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.
Supaluk PrachayasittikulCenter of Data Mining and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Bangkok 10700, Thailand.
Somsak RuchirawatLaboratory of Medicinal Chemistry and Program in Chemical Sciences, Chulabhorn Research Institute, Chulabhorn Graduate Institute, Bangkok 10210, Thailand.
Virapong PrachayasittikulDepartment of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok 10700, Thailand.
Ratchanok PingaewDepartment of Chemistry, Faculty of Science, Srinakharinwirot University, Bangkok 10110, Thailand.ORCID https://orcid.org/0000-0003-4977-5854

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidermal growth factor receptor (EGFR) has been recognized as one of the attractive targets for anticancer drug development. Herein, a set of anilino-1,4-naphthoquinone derivatives (

Identifiers

PMID35664590
PMCPMC9161259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.